Agenus (AGEN) Q2 2025 earnings summary

Executive summary

• Colorectal cancer incidence is rising among younger adults, with limited late-stage treatment options and a critical unmet need for effective therapies.

• BOT/BAL immunotherapy shows promising results, including 42% two-year survival and median overall survival of 21 months in late-stage MSS colorectal cancer, outperforming current standards.

• Entered into an asset purchase agreement to sell manufacturing operations to Zydus for $75M upfront, up to $50M in contingent payments, and a $16M equity investment, with closing expected in Q3 2025.

• Regulatory alignment secured for a streamlined two-arm Phase 3 BATTMAN trial, expected to launch globally in Q4 2025.

• Strategic partnerships and prudent financial management position the company for continued advancement, but substantial doubt remains about long-term viability due to ongoing funding needs.

Financial highlights

• Q2 YTD 2025 revenue was $49.8M, mainly from non-cash royalty revenue, with a net loss of $53.3M and operating loss of $30.0M.

• Cash and cash equivalents at June 30, 2025, were $9.5M–$20.2M, with a $91M capital infusion from Zydus expected in Q3 2025.

• Research and development expenses decreased 40% year-over-year to $48.2M for the six months ended June 30, 2025.

• Raised $18.6M from at-the-market equity offerings in the first half of 2025, with an additional $5.2M post-quarter.

• Debt outstanding as of June 30, 2025, was $35.8M in principal, with maturities in 2026.

Outlook and guidance

• BATTMAN Phase 3 trial for BOT/BAL in refractory MSS CRC to launch globally in Q4 2025, with rapid international enrollment targeted.

• Anticipates $91M from Zydus in Q3 2025, expected to satisfy liquidity needs through 2026, but additional funding is required for ongoing operations and product launches.

• Significant clinical data presentations and expanded evidence for BOT/BAL in multiple tumor types anticipated in 2H 2025.